Expert Interview
Discussing Allogene Therapeutics' Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma
Ticker(s): ALLO, BMY, GILD, PFE, RHHBY, MRKInstitution: Duke University Medical Center
- Chief, Division of Cell Therapy in the Department of Medicine
- Manages 30 patients with large B-cell lymphoma
- Research interests are in two broad areas, clinical hematopoietic stem cell and cord blood transplantation and in the laboratory studies related to graft vs. host disease and immune reconstitution
How many patients do you manage with Large B-Cell Lymphoma?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Cemacabtagene Ansegedleucel (Cema-Cel), an Allogeneic Anti-CD19 CAR-T Therapy for First-Line Consolidation in Large B-Cell Lymphoma?
Added By: lilly_adminDoes this early positive data translate to long-term clinical durability, specifically EFS?
Added By: lilly_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
